Search Tag: CAP
2025 12 Mar
Community-acquired pneumonia (CAP) is a leading cause of hospitalisation with high mortality. It can be caused by various pathogens, including viruses, bacteria, and fungi, complicating treatment. Adjuvant corticosteroid treatment may help reduce excessive inflammation, which is linked to higher mortality. While RCTs and a meta-analysis suggest...Read more
2024 26 Nov
Pneumonia is a major global health issue, particularly for critically ill patients in ICUs. It encompasses various types, such as community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP), each with distinct diagnostic and treatment challenges. Annually, pneumonia contributes to over 2.5 million...Read more
2024 14 May
Critical illness-related corticosteroid insufficiency (CIRCI) is commonly seen in criticall ill patients and involves systemic inflammation, hypothalamus–pituitary–adrenal axis dysregulation, altered cortisol metabolism, and tissue glucocorticoid resistance. A task force of international experts from the Society of Critical Care Medicine...Read more
2024 13 Feb
In a subgroup analysis of the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, researchers aimed to explore the effects of hydrocortisone plus fludrocortisone on patients with community-acquired pneumonia (CAP) compared to those with non-CAP-related septic shock. The goal was to determine whether glucocorticoids...Read more
2023 12 Sep
Corticosteroid use in the care of critically ill patients has been the subject of ongoing research with conflicting findings. There is a growing interest in understanding their role in treating a common source of sepsis: community-acquired pneumonia (CAP). Some studies have focused on determining whether corticosteroids provide clinical benefits to...Read more
